The commercialization of a rare disease drug often comes with complex challenges and subsequent risks from development through post-launch. Ensuring success takes understanding and improving every step of the patient’s treatment journey. AmerisourceBergen’s patient-centric approach and experience in the orphan drug market has identified best practices to help partners successfully commercialize their product.

Read more about our best practices in the full article by Nancy Pilcher.

Or explore the expertise and solutions we’ve used to expand access and commercialize

more than 100 rare disease treatments at ItTakesAmerisourceBergen.com

Follow us for additional insights: